295 related articles for article (PubMed ID: 22189395)
1. The molecular classification of medulloblastoma: driving the next generation clinical trials.
Leary SE; Olson JM
Curr Opin Pediatr; 2012 Feb; 24(1):33-9. PubMed ID: 22189395
[TBL] [Abstract][Full Text] [Related]
2. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
[TBL] [Abstract][Full Text] [Related]
3. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of intertumoral heterogeneity within medulloblastoma uncharted-pathway subtypes.
Li Z; Wei Y; Shao Y; Tang L; Gong J
Brain Tumor Pathol; 2021 Jul; 38(3):234-242. PubMed ID: 34180021
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
Thompson EM; Hielscher T; Bouffet E; Remke M; Luu B; Gururangan S; McLendon RE; Bigner DD; Lipp ES; Perreault S; Cho YJ; Grant G; Kim SK; Lee JY; Rao AAN; Giannini C; Li KKW; Ng HK; Yao Y; Kumabe T; Tominaga T; Grajkowska WA; Perek-Polnik M; Low DCY; Seow WT; Chang KTE; Mora J; Pollack IF; Hamilton RL; Leary S; Moore AS; Ingram WJ; Hallahan AR; Jouvet A; Fèvre-Montange M; Vasiljevic A; Faure-Conter C; Shofuda T; Kagawa N; Hashimoto N; Jabado N; Weil AG; Gayden T; Wataya T; Shalaby T; Grotzer M; Zitterbart K; Sterba J; Kren L; Hortobágyi T; Klekner A; László B; Pócza T; Hauser P; Schüller U; Jung S; Jang WY; French PJ; Kros JM; van Veelen MC; Massimi L; Leonard JR; Rubin JB; Vibhakar R; Chambless LB; Cooper MK; Thompson RC; Faria CC; Carvalho A; Nunes S; Pimentel J; Fan X; Muraszko KM; López-Aguilar E; Lyden D; Garzia L; Shih DJH; Kijima N; Schneider C; Adamski J; Northcott PA; Kool M; Jones DTW; Chan JA; Nikolic A; Garre ML; Van Meir EG; Osuka S; Olson JJ; Jahangiri A; Castro BA; Gupta N; Weiss WA; Moxon-Emre I; Mabbott DJ; Lassaletta A; Hawkins CE; Tabori U; Drake J; Kulkarni A; Dirks P; Rutka JT; Korshunov A; Pfister SM; Packer RJ; Ramaswamy V; Taylor MD
Lancet Oncol; 2016 Apr; 17(4):484-495. PubMed ID: 26976201
[TBL] [Abstract][Full Text] [Related]
6. Clustering of self-organizing map identifies five distinct medulloblastoma subgroups.
Cao C; Wang W; Jiang P
Cancer Biomark; 2016; 16(3):327-32. PubMed ID: 26889815
[TBL] [Abstract][Full Text] [Related]
7. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M; Hielscher T; Korshunov A; Northcott PA; Bender S; Kool M; Westermann F; Benner A; Cin H; Ryzhova M; Sturm D; Witt H; Haag D; Toedt G; Wittmann A; Schöttler A; von Bueren AO; von Deimling A; Rutkowski S; Scheurlen W; Kulozik AE; Taylor MD; Lichter P; Pfister SM
J Clin Oncol; 2011 Oct; 29(29):3852-61. PubMed ID: 21911727
[TBL] [Abstract][Full Text] [Related]
8. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
9. Medulloblastoma: From Myth to Molecular.
Ramaswamy V; Taylor MD
J Clin Oncol; 2017 Jul; 35(21):2355-2363. PubMed ID: 28640708
[TBL] [Abstract][Full Text] [Related]
10. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial.
Robinson GW; Rudneva VA; Buchhalter I; Billups CA; Waszak SM; Smith KS; Bowers DC; Bendel A; Fisher PG; Partap S; Crawford JR; Hassall T; Indelicato DJ; Boop F; Klimo P; Sabin ND; Patay Z; Merchant TE; Stewart CF; Orr BA; Korbel JO; Jones DTW; Sharma T; Lichter P; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Sanders RP; Onar-Thomas A; Ellison DW; Gajjar A; Northcott PA
Lancet Oncol; 2018 Jun; 19(6):768-784. PubMed ID: 29778738
[TBL] [Abstract][Full Text] [Related]
12. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
13. The clinical implications of medulloblastoma subgroups.
Northcott PA; Korshunov A; Pfister SM; Taylor MD
Nat Rev Neurol; 2012 May; 8(6):340-51. PubMed ID: 22565209
[TBL] [Abstract][Full Text] [Related]
14. Genetics of medulloblastoma: clues for novel therapies.
Onvani S; Etame AB; Smith CA; Rutka JT
Expert Rev Neurother; 2010 May; 10(5):811-23. PubMed ID: 20420498
[TBL] [Abstract][Full Text] [Related]
15. Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles.
Korshunov A; Sahm F; Okonechnikov K; Ryzhova M; Stichel D; Schrimpf D; Casalini B; Sievers P; Meyer J; Zheludkova O; Golanov A; Lichter P; Jones DTW; Pfister SM; Kool M; von Deimling A
Acta Neuropathol; 2019 Jun; 137(6):1003-1015. PubMed ID: 30826918
[TBL] [Abstract][Full Text] [Related]
16. The proteomic analysis shows enrichment of RNA surveillance pathways in adult SHH and extensive metabolic reprogramming in Group 3 medulloblastomas.
Kp M; Kumar A; Biswas D; Moiyadi A; Shetty P; Gupta T; Epari S; Shirsat N; Srivastava S
Brain Tumor Pathol; 2021 Apr; 38(2):96-108. PubMed ID: 33438046
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma-translating discoveries from the bench to the bedside.
Gajjar AJ; Robinson GW
Nat Rev Clin Oncol; 2014 Dec; 11(12):714-22. PubMed ID: 25348790
[TBL] [Abstract][Full Text] [Related]
18. New Approaches in Targeted Therapy for Medulloblastoma in Children.
Maier H; Dalianis T; Kostopoulou ON
Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Pediatric Medulloblastoma.
Jackson K; Packer RJ
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):841-848. PubMed ID: 37943476
[TBL] [Abstract][Full Text] [Related]
20. Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.
Newton HB
Expert Opin Investig Drugs; 2001 Dec; 10(12):2089-104. PubMed ID: 11772307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
